Pembrolizumab Antibody

SKU: orb1297806

Description

Pembrolizumab is a humanized anti-PD-1 monoclonal antibody used in research to block the PD-1/PD-L1 interaction, thereby restoring T-cell-mediated tumor killing. It is widely applied in immuno-oncology research for both in vitro T-cell activation assays and in vivo preclinical cancer models.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 1374853-91-4
• MW: 149 kDa
• Purity: 98.00%
• Target: PD-1/PD-L1

Bioactivity

• Target IC50:
  T cells:0.535 µg/mL|PD-1:0.6 nM
• In Vivo:
  METHODS: In the open-label, international, multicenter extension cohort of the phase 1 KEYNOTE-001 trial, patients with advanced melanoma who progressed after 2 or more doses of ipilimumab were randomly assigned to receive 2 mg/kg every 3 weeks or Treatment with Pembrolizumab (MK-3475)10 mg/kg. RESULTS Among the 173 patients treated (2 mg/kg, N = 89; 10 mg/kg, N = 84), the ORR was nearly identical at 26% for both doses, 73% and 68%, respectively. of patients showed reduction in target lesion size. METHODS: Patients were randomly assigned to intravenous pembrolizumab 200 mg every 3 weeks for ≤35 cycles of pembrolizumab or until disease progression, unacceptable toxicity, or discontinuation. Imaging was performed at week 9, then every 6 weeks until year 1, and every 9 weeks thereafter. RESULTS The median OS of pembrolizumab was 14.9 months (95% CI, 11.5-20.6), and it could improve OS in the PD-L1 CPS ≥ 20 and CPS ≥ populations, and the DOR was also significantly longer.
• In Vitro:
  METHODS: Peripheral blood mononuclear cells (PBMC) from healthy donors (HD) and primary breast cancer (PBC) were cultured for 24 hours (with plate-bound anti-CD3 and anti-CD28 antibodies for activated cells) and treated with 2 μg/ul Pembrolizumab (MK-3475) treatment (for treated cells) stains intracellular expression of CD4, PD-1 surface marker, and CTLA-4. RESULTS In CD4 T cells, PD-1 expression was significantly higher in PBC patients compared with steady-state HD. Pembrolizumab treatment significantly reduced PD-1 expression in CD4 T cells in both cohorts of non-activated and activated PBMC. METHODS: After HCCLM3 and SK-HEP.1 cells were lysed, 10 ng/mL TNF-α and 10 ng/mL IL-1β were added to the medium of DC and incubated for 48 hours. Finally, DCs were co-cultured with CIK cells at a ratio of 1:10 for 2 days, and on day 12, pembrolizumab 20 ug/mL was added to DC-CIK cells to mediate PD-1 blockade. RESULTS pembrolizumab treatment increased DC-CIK cell proliferation, indicating that pembrolizumab enhanced DC-CIK cell cytotoxicity against HCC cell lines.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Pembrolizumab, Pembrolizumab(anti-PD-1), PDL1, PD-L1, PD1, PD-1, PD1/PDL1, anti-PD-1

Quick Database Links

Gene Symbol

PD-1/PD-L1